BENGALURU, India, Dec. 6, 2024 /PRNewswire/ -- In a significant step towards ensuring care for patients with disease-related suffering, Microland Foundation,…
Media ReleaseCOPENHAGEN, Denmark; December 7, 2024 Results show 96 percent overall response rate (ORR), 87 percent complete response (CR), and…
Head-to-head exploratory cohort of a Phase 3 trial showed first-in-class poze-cemdi combination treatment helped patients achieve and maintain greater disease…
Data from the ongoing Phase 1/2 ATALANTA-1 study in a heavily pretreated R/R NHL patient population demonstrate high antitumor activity…
BENGALURU, India, Dec. 6, 2024 /PRNewswire/ -- In a significant step towards ensuring care for patients with disease-related suffering, Microland Foundation,…
BENGALURU, India, Dec. 6, 2024 /PRNewswire/ -- In a significant step towards ensuring care for patients with disease-related suffering, Microland Foundation,…
BENGALURU, India, Dec. 6, 2024 /PRNewswire/ -- In a significant step towards ensuring care for patients with disease-related suffering, Microland Foundation,…
BENGALURU, India, Dec. 6, 2024 /PRNewswire/ -- In a significant step towards ensuring care for patients with disease-related suffering, Microland Foundation,…
In the Phase IIIB APPULSE-PNH study, oral Fabhalta® (iptacopan) improved the average hemoglobin (Hb) level versus baseline in adult patients…
BTL, a leader in medical innovation, is proud to announce a major milestone: the successful treatment of the first patients…